These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 21544815)

  • 1. Targeting of pancreatic and prostate cancer stem cell characteristics by Crambe crambe marine sponge extract.
    Ottinger S; Klöppel A; Rausch V; Liu L; Kallifatidis G; Gross W; Gebhard MM; Brümmer F; Herr I
    Int J Cancer; 2012 Apr; 130(7):1671-81. PubMed ID: 21544815
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aspirin counteracts cancer stem cell features, desmoplasia and gemcitabine resistance in pancreatic cancer.
    Zhang Y; Liu L; Fan P; Bauer N; Gladkich J; Ryschich E; Bazhin AV; Giese NA; Strobel O; Hackert T; Hinz U; Gross W; Fortunato F; Herr I
    Oncotarget; 2015 Apr; 6(12):9999-10015. PubMed ID: 25846752
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sulforaphane increases drug-mediated cytotoxicity toward cancer stem-like cells of pancreas and prostate.
    Kallifatidis G; Labsch S; Rausch V; Mattern J; Gladkich J; Moldenhauer G; Büchler MW; Salnikov AV; Herr I
    Mol Ther; 2011 Jan; 19(1):188-95. PubMed ID: 20940707
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A combination of DR5 agonistic monoclonal antibody with gemcitabine targets pancreatic cancer stem cells and results in long-term disease control in human pancreatic cancer model.
    Rajeshkumar NV; Rasheed ZA; García-García E; López-Ríos F; Fujiwara K; Matsui WH; Hidalgo M
    Mol Cancer Ther; 2010 Sep; 9(9):2582-92. PubMed ID: 20660600
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synergistic activity of sorafenib and sulforaphane abolishes pancreatic cancer stem cell characteristics.
    Rausch V; Liu L; Kallifatidis G; Baumann B; Mattern J; Gladkich J; Wirth T; Schemmer P; Büchler MW; Zöller M; Salnikov AV; Herr I
    Cancer Res; 2010 Jun; 70(12):5004-13. PubMed ID: 20530687
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel role of pancreatic differentiation 2 in facilitating self-renewal and drug resistance of pancreatic cancer stem cells.
    Vaz AP; Ponnusamy MP; Rachagani S; Dey P; Ganti AK; Batra SK
    Br J Cancer; 2014 Jul; 111(3):486-96. PubMed ID: 25003666
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metformin inhibits cell proliferation, migration and invasion by attenuating CSC function mediated by deregulating miRNAs in pancreatic cancer cells.
    Bao B; Wang Z; Ali S; Ahmad A; Azmi AS; Sarkar SH; Banerjee S; Kong D; Li Y; Thakur S; Sarkar FH
    Cancer Prev Res (Phila); 2012 Mar; 5(3):355-64. PubMed ID: 22086681
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exosomes derived from cancer stem cells of gemcitabine-resistant pancreatic cancer cells enhance drug resistance by delivering miR-210.
    Yang Z; Zhao N; Cui J; Wu H; Xiong J; Peng T
    Cell Oncol (Dordr); 2020 Feb; 43(1):123-136. PubMed ID: 31713003
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination of salinomycin and gemcitabine eliminates pancreatic cancer cells.
    Zhang GN; Liang Y; Zhou LJ; Chen SP; Chen G; Zhang TP; Kang T; Zhao YP
    Cancer Lett; 2011 Dec; 313(2):137-44. PubMed ID: 22030254
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemosensitization and inhibition of pancreatic cancer stem cell proliferation by overexpression of microRNA-205.
    Chaudhary AK; Mondal G; Kumar V; Kattel K; Mahato RI
    Cancer Lett; 2017 Aug; 402():1-8. PubMed ID: 28536008
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of glucose turnover by 3-bromopyruvate counteracts pancreatic cancer stem cell features and sensitizes cells to gemcitabine.
    Isayev O; Rausch V; Bauer N; Liu L; Fan P; Zhang Y; Gladkich J; Nwaeburu CC; Mattern J; Mollenhauer M; Rückert F; Zach S; Haberkorn U; Gross W; Schönsiegel F; Bazhin AV; Herr I
    Oncotarget; 2014 Jul; 5(13):5177-89. PubMed ID: 25015789
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined gemcitabine and CHK1 inhibitor treatment induces apoptosis resistance in cancer stem cell-like cells enriched with tumor spheroids from a non-small cell lung cancer cell line.
    Fang DD; Cao J; Jani JP; Tsaparikos K; Blasina A; Kornmann J; Lira ME; Wang J; Jirout Z; Bingham J; Zhu Z; Gu Y; Los G; Hostomsky Z; Vanarsdale T
    Front Med; 2013 Dec; 7(4):462-76. PubMed ID: 23820871
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Autophagy mediates survival of pancreatic tumour-initiating cells in a hypoxic microenvironment.
    Rausch V; Liu L; Apel A; Rettig T; Gladkich J; Labsch S; Kallifatidis G; Kaczorowski A; Groth A; Gross W; Gebhard MM; Schemmer P; Werner J; Salnikov AV; Zentgraf H; Büchler MW; Herr I
    J Pathol; 2012 Jul; 227(3):325-35. PubMed ID: 22262369
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Side population cells of pancreatic cancer show characteristics of cancer stem cells responsible for resistance and metastasis.
    Niess H; Camaj P; Renner A; Ischenko I; Zhao Y; Krebs S; Mysliwietz J; Jäckel C; Nelson PJ; Blum H; Jauch KW; Ellwart JW; Bruns CJ
    Target Oncol; 2015 Jun; 10(2):215-27. PubMed ID: 24950733
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Notch signaling pathway targeted therapy suppresses tumor progression and metastatic spread in pancreatic cancer.
    Yabuuchi S; Pai SG; Campbell NR; de Wilde RF; De Oliveira E; Korangath P; Streppel MM; Rasheed ZA; Hidalgo M; Maitra A; Rajeshkumar NV
    Cancer Lett; 2013 Jul; 335(1):41-51. PubMed ID: 23402814
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synergistic antitumor interaction of valproic acid and simvastatin sensitizes prostate cancer to docetaxel by targeting CSCs compartment via YAP inhibition.
    Iannelli F; Roca MS; Lombardi R; Ciardiello C; Grumetti L; De Rienzo S; Moccia T; Vitagliano C; Sorice A; Costantini S; Milone MR; Pucci B; Leone A; Di Gennaro E; Mancini R; Ciliberto G; Bruzzese F; Budillon A
    J Exp Clin Cancer Res; 2020 Oct; 39(1):213. PubMed ID: 33032653
    [TBL] [Abstract][Full Text] [Related]  

  • 17. JNK pathway inhibition selectively primes pancreatic cancer stem cells to TRAIL-induced apoptosis without affecting the physiology of normal tissue resident stem cells.
    Recio-Boiles A; Ilmer M; Rhea PR; Kettlun C; Heinemann ML; Ruetering J; Vykoukal J; Alt E
    Oncotarget; 2016 Mar; 7(9):9890-906. PubMed ID: 26840266
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Concomitant targeting of multiple key transcription factors effectively disrupts cancer stem cells enriched in side population of human pancreatic cancer cells.
    Wang X; Liu Q; Hou B; Zhang W; Yan M; Jia H; Li H; Yan D; Zheng F; Ding W; Yi C; Hai Wang
    PLoS One; 2013; 8(9):e73942. PubMed ID: 24040121
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined targeted treatment to eliminate tumorigenic cancer stem cells in human pancreatic cancer.
    Mueller MT; Hermann PC; Witthauer J; Rubio-Viqueira B; Leicht SF; Huber S; Ellwart JW; Mustafa M; Bartenstein P; D'Haese JG; Schoenberg MH; Berger F; Jauch KW; Hidalgo M; Heeschen C
    Gastroenterology; 2009 Sep; 137(3):1102-13. PubMed ID: 19501590
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Curcumin sensitizes pancreatic cancer cells to gemcitabine by attenuating PRC2 subunit EZH2, and the lncRNA PVT1 expression.
    Yoshida K; Toden S; Ravindranathan P; Han H; Goel A
    Carcinogenesis; 2017 Oct; 38(10):1036-1046. PubMed ID: 29048549
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.